Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis

Lung cancer remains the leading cause of cancer death worldwide [1]. A majority of lung cancers can be classified as non-small cell lung cancer (NSCLC), the largest group of which are adenocarcinomas. The management of metastatic NSCLC (mNSCLC) adenocarcinoma depends on the presence or absence of an oncogenic driver mutation. The list of targetable mutations in oncogene driven mNSCLC now includes epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, KRAS-G12C, NTRK, BRAF, MET, RET, PIK3CA, MEK, ERBB2 and the list is expected to grow [2 –4].

Source: Lung Cancer - April 18, 2020 Category: Cancer & Oncology Authors: Daniel Breadner, Phillip Blanchette, Sumugan Shanmuganathan, Ronald Gabriel Boldt, Jacques Raphael Source Type: research